Persica Pharmaceuticals announces positive Phase 1b clinical data for PP353, a novel, non-opioid intradiscal injection for the treatment of chronic Low Back Pain Persica Pharmaceuticals announces positive Phase 1b clinical data for PP353, a novel, non-opioid intradiscal injection for the treatment of chronic Low Back Pain The PP353 clinical trial met the...

Persica Pharmaceuticals’ research published in Journal of Orthopaedic Research Spine ahead of anticipated clinical data in 2025 Persica Pharmaceuticals’ research published in Journal of Orthopaedic Research Spine ahead of anticipated clinical data in 2025 Persica is developing PP353, a potentially curative, opioid-sparing...

Persica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back pain Persica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back pain London, UK, 07 March 2024 – Persica Pharmaceuticals Ltd, a privately held,...

Peter Hamlyn, Founder and Director of Persica Pharmaceuticals will be presenting at the British Association of Spine Surgeons Peter Hamlyn, Founder and Director of Persica Pharmaceuticals will be presenting at the British Association of Spine Surgeons London, UK, 24 March 2022 – Persica Pharmaceuticals Ltd, a clinical stage...

Persica Pharmaceuticals has completed the first stage of its clinical trial on unique injectable PP353, to treat chronic lower back pain Persica Pharmaceuticals has completed the first stage of its clinical trial on unique injectable PP353, to treat chronic lower back pain Novel approach applicable to 20% of all CLBP populationsFirst...